 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
S-1 Dated: 2/7/00 Offering Amount: $100,000,000 Underwriters: Warberg Dillon Read Lehman Bros. Dain Rausher Company Description (COPIED FROM EDGAR) Luminex Corporation has developed, manufactures and markets a proprietary technology platform that simplifies biological testing for the life sciences industry. This industry depends on a broad range of tests, called bioassays, to discover new drugs, identify new genes or simply monitor blood cholesterol levels. The LabMAP system is able to simultaneously perform up to 100 bioassays on a single drop of fluid. This is accomplished with a compact instrument, the Luminex 100, that reads biological tests taking place on the surface of microscopic plastic beads called microspheres. The Luminex 100 combines this miniaturized bioassay capability with diode lasers, digital signal processors and proprietary software to create a system offering significant advantages in speed, precision, flexibility and cost. We believe our LabMAP technology is broadly applicable in the fields of drug discovery, clinical diagnostics, genetic analysis, biomedical research and pharmacogenomics. We began marketing the current generation of LabMAP in 1999. As of January 31,2000, 63 life sciences customers have purchased 100 LabMAP systems. Our customers include GlaxoWellcome plc, SmithKline Beecham Corporation, Eli Lilly & Company, Laboratory Corporation of America, Genentech Inc., Abbott Laboratories, Life Technologies Inc., Bio-Rad Laboratories, Inc., Lawrence Livermore National Laboratories, Mayo Clinic, Centers for Disease Control and Prevention and National Institutes of Health. OUR MARKET OPPORTUNITY Bioassays are used extensively throughout the life sciences industry to detect the presence of certain biochemicals, proteins or genes in a sample. They are broadly used in drug discovery, genetic analysis, pharmacogenomics, clinical diagnostics and general biomedical research. For example, bioassays can be used to: .measure the affinity between a chemical compound and a disease target for drug discovery and development; .assist physicians in prescribing the appropriate drug therapy to match the patient's unique genetic makeup, a process known as pharmacogenomics; .detect genetic variations, such as single nucleotide polymorphisms or SNPs; and .measure the presence and quantity of biochemicals in blood to assist physicians in diagnosing, treating and monitoring pathological conditions such as heart attack or diabetes. Bioassays are either developed internally to meet the specific needs of the laboratory or purchased in the form of an off-the-shelf test kit or customized service. According to industry reports, the global market for tools used to develop and perform bioassays is estimated to have been approximately $27.5 billion in 1998 and is expected to grow at an annual rate of 8%. There are a number of factors contributing to this increase, including: .increased research and development spending by pharmaceutical and biomedical research companies; .a shift in research and development focus from gene sequencing to functional genomics and proteomics; .increased demand for disease-specific diagnostic tests; .application of disease targets from drug discovery into in vitro diagnostics; and .evolution of pharmacogenomics. The differing bioassay needs of life sciences laboratories have led to the development of specialized techniques and instrumentation. As a result, most of these laboratories have become highly compartmentalized. For example, clinical testing facilities are organized into functional groups, such as chemistry, microbiology, immunology and serology. Similarly, pharmaceutical laboratories are separated by disease target, such as cancer and hypertension, as well as by the stages of the drug discovery process, from initial bioassay development to toxicology. This has created inefficiencies in laboratories since they must now purchase multiple instruments, often from different vendors, to meet their testing needs. This limits the laboratories' ability to standardize bioassay techniques, operator training and hardware maintenance. THE LUMINEX SOLUTION Our solution is to provide a single platform, the LabMAP technology, that can perform a wide range of bioassays in a cost-effective manner. The key features of our platform include the following: .performs multiple tests simultaneously; .flexible in customizing bioassays comprised of multiple tests; .high throughput; .ease of use; and .low cost to purchase and operate. OUR STRATEGY Our goal is to establish our LabMAP system as the industry standard for performing bioassays. To achieve this goal, we have implemented the following strategy: .focus on large, fast-growing segments of the life sciences industry; .continue to develop strategic partnerships to broaden and accelerate market acceptance of our LabMAP technology; .provide an open platform that allows customers to design bioassays using a single platform; .expand the functionality of the LabMAP product line; and .allow easy technology access to encourage rapid market adoption. THE FOREGOING DOES NOT REPRESENT AN OFFER TO BUY OR SELL THE SECURITES OF THIS OR ANY CORPORATION AS THE OFFERING IS MADE BY PROSPECTUS ONLY | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2026 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |